Nanologica AB NICA

OMXSTO · Sweden · Health Technology

SEK 0.3020-0.00 (-1.31%)

Market closed· Oct 1, 2026, 3:11 PM UTC· SEK · Data may be delayed

Prices may be delayed and are for informational purposes only - not investment advice.

Nanologica AB NICA

OMXSTO · Sweden · Health Technology

SEK 0.3020-0.00 (-1.31%)

Market closed· Oct 1, 2026, 3:11 PM UTC· SEK · Data may be delayed

Prices may be delayed and are for informational purposes only - not investment advice.

-22.76% · 6MFull-screen chart

Open SEK 0.3140High SEK 0.3140Low SEK 0.2930Close SEK 0.3020Volume 693.83K

Oct 1, 2026

Charts by TradingView Lightweight Charts

Key statistics

Previous close: SEK 0.3060
Day range: SEK 0.2930 – SEK 0.3140
52-week range: SEK 0.2860 – SEK 2.25
Volume: 693.83K
Market cap: SEK 100.60M
P/E (TTM): 1.4
Next earnings date: 2026-11-26
Avg. volume (1Y): 1.37M

Performance

1 week

-3.21%

1 month

-17.49%

3 months

-39.11%

6 months

-19.47%

Year to date

-59.73%

1 year

-76.59%

Total return, dividends included.

Company profile

Sector: Health Technology
Industry: Pharmaceuticals: Major
Country: Sweden
Exchange: OMXSTO
Shares outstanding: 328.77M
Employees: 19
ISIN: SE0005454873
Beta: 0.75

Technical view

Below averages

Where the price sits against its 50- and 200-day moving averages.

Valuation & analysis

Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.

News

Yahoo FinanceJan 29, 2026

Ardena completes divestment of its Södertälje drug substance site in Sweden to Nanologica

GMP Reactor Operations Reactor systems supporting drug substance manufacturing operations Ghent, Belgium, 29th January 2026 – Ardena, a specialist CDMO and bioanalytical CRO enabling precision medicines and other complex therapies, today announced that it has completed the divestment of its drug substance (API) site in Södertälje, Sweden, to Nanologica AB. The business will operate as a wholly owned subsidiary within the Nanologica Group and will revert to its original name, Syntagon AB. The Söd

Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.